| 2.66 Data as of May 17 |  +0.02 / +0.76%Today’s Change | 1.99 Today|||52-Week Range 12.88 | +23.15% Year-to-Date |
| Previous close | 2.64 |
| Today’s open | 2.66 |
| Day’s range | 2.64 - 2.69 |
| Volume | 48,915 |
| Average volume (3 months) | 132,466 |
| Market cap | $52.1M |
| Dividend yield | -- |
| Earnings growth (last year) | +45.44% |
| Earnings growth (this year) | +55.28% |
| Earnings growth (next 5 years) | -15.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 1.93 |
| Today’s change | Today’s % change | |
|---|---|---|
| CMXICytomedix Inc | 0.00 | 0.00% |
| NBYNovaBay Pharmaceutic... | +0.01 | +0.71% |
| ATNMCactus Ventures Inc | -0.05 | -1.28% |
| CYCCCyclacel Pharmaceuti... | +0.04 | +1.33% |
| Next reporting date | May 29, 2013 |
| EPS forecast (this quarter) | -$0.21 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$24.8M |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman, Chief Executive & Medical officer Russell H. Ellison, MD |
Chief Financial Officer & Head-Investor Relations David J. Barrett, CPA |
Corporate headquarters New York, New York |
.
